In this video, Esther M. Bowie, MD, discusses results of the GALE study, presented at the American Academy of Ophthalmology meeting.
The open-label extension study found a 35% reduction in geographic atrophy in patients who received pegcetacoplan every month and an approximately 24% reduction in patients who received it every other month, according to Bowie, a professor of ophthalmology at Penn State Health Milton S. Hershey Medical Center.
“We’re seeing delayed or slowing progression of geographic atrophy,” she said of the results.
Some patients experienced inflammation and